The Ding Lab is deeply connected to many large-scale cancer research consortium projects.

Click to learn more about each project!

Clinical Proteomic Tumor Analysis Consortium (CPTAC)

Image source:

Image source:

The NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) is the first large-scale project to integrate genomics and proteomics data, with the goal of understanding of cancer driver events and developing novel therapies. CPTAC was launched in 2011 with pioneering proteogenomic studies of breast, ovarian and colorectal cancers (CPTAC2) and now has expanded to characterize ten additional cancer types (CPTAC3). CPTAC3 utilizes state-of-the-art shotgun protein identification and quantification by mass spectrometry to collect protein, phosphoprotein, acetylated protein, and glycoprotein data. The integration of several omics data – genomics, transcriptomics, proteomics, phosphoproteomics etc. – provides power to address issues of cancer therapeutic resistance and toxicity by elucidating cancer-relevant pathways through post-translational modifications. As one of CPTAC3’s Proteogenomic Data Analysis Centers, the Ding lab contributes to genomic data processing and analysis and, at the same time, is actively building expertise in proteomics and phosphoproteomics.

Human Tumor Atlas Network (HTAN)

The Human Tumor Atlas Network (HTAN) project at Washington University integrates cutting-edge technologies to study breast and pancreatic cancers. It is a large-scale effort to understand the life histories of tumors, including how normal cells become cancerous; how the cancer evolves in response to treatment; and what changes must occur for the tumor to become resistant to therapy and spread. The project takes advantage of the most advanced technologies, such as single cell sequencing, making possible studies that could not be conducted until very recently. The Ding Lab plays a leading role in this effort at Wash U, performing a variety of bioinformatics and imaging analyses.

Multiple Myeloma (MM)


We are deeply involved in collaborations at WashU aiming to better understand multiple myeloma, both the mechanisms of disease progression and the advancement of treatment options. By integrating the resources and expertise of clinical research teams at the Washington University School of Medicine and the Multiple Myeloma Research Foundation (MMRF), our investigations promote the discovery druggable targets by using cutting-edge genomics and proteomics technologies. In addition, major efforts from our lab contribute to understanding the dynamic relationship between the tumor and microenvironment in multiple myeloma.

PDX Development and Trial Centers Research Network (PDXNet)


The National Cancer Institute launched the PDX (patient-derived xenografts) Development and Trial Centers Research Network (PDXNet) in September 2017 to accelerate translational research using PDX datasets. The overall goal of work at Wash U is to exploit the translational potential of PDX models for evaluating the response of various treatments in models with specific molecular characteristics. Work in the Ding Lab includes development of bioinformatics algorithms for the genomic and proteomic characterization and analysis of PDX models and the development of databases to support this initiative.

The Cancer Genome Atlas (TCGA)


The Cancer Genome Atlas (TCGA) is a foundational large-scale cancer genomics data set which has revolutionized the way cancer is studied, leading to new understandings of cancer biology and treatment options. Since 2006, data from over 11,000 patients representing 33 cancer types, including tumor and normal whole exome and whole genome sequencing, RNA and protein expression, and clinical characteristics, has come to represent the first phase of cancer genomics. The Ding Lab served as a leader of several TCGA projects, including methods for identifying cancer driver genes, detecting germline variants, and integrating genomics and proteomics data, all at a large computational scale. The lessons learned and experience gained as TCGA leaders have given the Ding Lab a unique role in the next phase of cancer genomics and proteomics.


  • Pediatric Cancer Genome Project (PCGP): A collaboration between St. Jude Children's Research Hospital and Washington University, aimed at understanding the genetic origins of childhood cancers

  • International Cancer Genome Consortium (ICGC): A project that obtains a comprehensive description of genomic, transcriptomic and epigenomic changes in 50 different tumor types and/or subtypes which are of clinical and societal importance across the globe

  • 1000 Genomes Structural Variation Project: A collaboration to characterize and detect genomic structural variants existing in the human genome